# An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

> **NCT05315713** · PHASE1,PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 8 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma, Follicular Lymphoma

## Interventions

- **DRUG:** Mosunetuzumab SC
- **DRUG:** Tiragolumab
- **DRUG:** Atezolizumab
- **OTHER:** Tocilizumab

## Key facts

- **NCT ID:** NCT05315713
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-10
- **Primary completion:** 2023-07-19
- **Final completion:** 2023-07-19
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Study was terminated due to Sponsor decision.
- **Last updated:** 2024-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05315713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05315713, "An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05315713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*